Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
RA Gupta, RN DuBois - Nature Reviews Cancer, 2001 - nature.com
RA Gupta, RN DuBois
Nature Reviews Cancer, 2001•nature.comPopulation-based studies have established that long-term intake of non-steroidal anti-
inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of
cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These
studies led to the identification of a molecular target, COX-2, that is involved in tumour
promotion during colorectal cancer progression. Recent studies in humans indicate that
therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer …
inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of
cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These
studies led to the identification of a molecular target, COX-2, that is involved in tumour
promotion during colorectal cancer progression. Recent studies in humans indicate that
therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer …
Abstract
Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.
nature.com
